Heart Beam, Inc. BEAT
We take great care to ensure that the data presented and summarized in this overview for HeartBeam, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BEAT
View all-
Vanguard Group Inc Valley Forge, PA1.12MShares$1.74 Million0.0% of portfolio
-
Smith, Salley & Associates368KShares$573,5290.03% of portfolio
-
Geode Capital Management, LLC Boston, MA294KShares$458,0120.0% of portfolio
-
Ubs Group Ag193KShares$300,3820.0% of portfolio
-
Kestra Private Wealth Services, LLC176KShares$274,5420.0% of portfolio
-
O'Shaughnessy Asset Management, LLC Stamford, CT139KShares$217,1230.0% of portfolio
-
Ritholtz Wealth Management139KShares$217,1230.0% of portfolio
-
Stifel Financial Corp St. Louis, MO100KShares$156,0000.0% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL88.1KShares$137,3580.0% of portfolio
-
Cannon Financial Strategists, Inc. Athens, GA78.7KShares$122,8320.02% of portfolio
Latest Institutional Activity in BEAT
Top Purchases
Top Sells
About BEAT
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Insider Transactions at BEAT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2025
|
Richard Ferrari Director |
BUY
Open market or private purchase
|
Direct |
29,412
+14.1%
|
$29,412
$1.7 P/Share
|
|
Feb 14
2025
|
Tim Cruickshank CFO |
BUY
Open market or private purchase
|
Direct |
17,647
+50.0%
|
$17,647
$1.7 P/Share
|
|
Sep 06
2024
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
1,674
-2.85%
|
$3,348
$2.34 P/Share
|
|
Aug 30
2024
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,500
-8.55%
|
$11,000
$2.31 P/Share
|
|
Aug 27
2024
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
2,194
-3.3%
|
$4,388
$2.26 P/Share
|
|
Aug 26
2024
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
300
-0.45%
|
$600
$2.38 P/Share
|
|
Aug 23
2024
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
2,500
-3.61%
|
$5,000
$2.3 P/Share
|
|
Jun 12
2024
|
Kenneth Warwick Nelson Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+20.7%
|
-
|
|
Jun 12
2024
|
Michael R Jaff Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+30.64%
|
-
|
|
Jun 12
2024
|
Willem Elfrink Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+9.45%
|
-
|
|
Jun 12
2024
|
Mark E Strome > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+36.74%
|
-
|
|
Jun 12
2024
|
George De Urioste Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+32.38%
|
-
|
|
Jun 12
2024
|
Marga Ortigas Wedekind Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+22.81%
|
-
|
|
Jun 12
2024
|
Richard Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,247
+22.81%
|
-
|
|
Sep 29
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,500
-13.21%
|
$11,000
$2.06 P/Share
|
|
Sep 28
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
8,000
-16.12%
|
$16,000
$2.04 P/Share
|
|
Sep 27
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
1,834
-3.56%
|
$3,668
$2.11 P/Share
|
|
Sep 26
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,000
-8.86%
|
$10,000
$2.09 P/Share
|
|
Sep 22
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
2,393
-4.07%
|
$4,786
$2.21 P/Share
|
|
Sep 21
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
100
-0.17%
|
$200
$2.41 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 47.1K shares |
|---|